Synthesis and In Vitro and In Vivo Evaluation of [3H]LRRK2-IN-1 as a Novel Radioligand for LRRK2
- 428 Downloads
LRRK2 (leucine-rich repeat kinase 2) has recently been proven to be a promising drug target for Parkinson’s disease (PD) due to an apparent enhanced activity caused by mutations associated with familial PD. To date, there have been no reports in which a LRRK2 inhibitor has been radiolabeled and used for in in vitro or in vivo studies of LRRK2. In the present study, we radiolabeled the LRRK2 ligand, LRRK-IN-1, for the purposes of performing in vitro (IC50, K d , B max, autoradiography) and in vivo (biodistribution, and blocking experiments) evaluations in rodents and human striatum tissues.
[3H]LRRK2-IN-1 was prepared with high radiochemical purity (>99 %) and a specific activity of 41 Ci/mmol via tritium/hydrogen (T/H) exchange using Crabtree’s catalyst. For IC50, K d , and B max determination, LRRK2-IN-1 was used as a competing drug for nonspecific binding assessment. The specific binding of the tracer was further evaluated via an in vivo blocking study in mice with a potent LRRK2 inhibitor, Pf-06447475.
In vitro binding studies demonstrated a saturable binding site for [3H]LRRK2-IN-1 in rat kidney, rat brain striatum and human brain striatum with K d of 26 ± 3 and 43 ± 8, 48 ± 2 nM, respectively. In rat, the density of LRRK2 binding sites (B max) was higher in kidney (6.4 ± 0.04 pmol/mg) than in brain (2.5 ± 0.03 pmol/mg), however, in human brain striatum, the B max was 0.73 ± 0.01 pmol/mg protein. Autoradiography imaging in striatum of rat and human brain tissues gave results consistent with binding studies. In in vivo biodistribution and blocking studies in mice, co-administration with Pf-06447475 (10 mg/kg) reduced the uptake of [3H]LRRK2-IN-1 (%ID/g) by 50–60% in the kidney or brain.
The high LRRK2 brain density observed in our study suggests the feasibility for positron emission tomography imaging of LRRK2 (a potential target) with radioligands of higher affinity and specificity.
Key WordsLRRK2 Parkinson’s disease LRRK2-IN-1 PET Autoradiography Bmax Bmax/Kd
The work is supported by the Center for Advanced Imaging Innovation and Research (CAI2R, www.cai2r.net) at New York University School of Medicine is supported by NIH/NIBIB grant number P41 EB017183. We would like to acknowledge the expert assistance of Mr. Yianni Piyis (METIS Laboratories) for help with the sectioning.
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
- 15.Daechsel JC, Farrer MJ (2010) LRRK2 and Parkinson disease. Arch Neurol 67:542–547Google Scholar
- 30.Henderson JL, Kormos BL, Hayward MM et al (2015) Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2, 3-d]pyrimidin-5-yl] benzonitrile (Pf-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor. J Med Chem 58:419–432CrossRefPubMedGoogle Scholar
- 34.Gray NS, Waller D, Choi HG et al (2014) Pyrimido-diazepinone compounds and methods of treating disorders. Patent: WO 2014145909:A3Google Scholar
- 50.Quirion R, Pilapil C, Allaoua H et al (1995) Autoradiographic distribution of multiple opioid, sigma and phencyclidine receptor binding sites in the human brain. In: Biegon A, Volkow ND (eds) ISBN: 084937653XSites of drug action in the human brain, pp 117–141Google Scholar
- 55.Thermofisher Tools and protocols on kinase basic module—theory: https://tools.thermofisher.com/content/sfs/manuals/LRRK2_G2019S_LanthaScreen_Activity.pdf